Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2013

01-09-2013 | Letter to the Editor

Immune aregenerative anemia without erythroblastopenia: a previously undescribed condition

Authors: V. Brousse, C. Brouzes, F. Sicre de Fontbrune, N. Casadevall, B. Varet

Published in: Annals of Hematology | Issue 9/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Dessypris EN, Krantz SB, Roloff JS, Lukens JN (1982) Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of children. Blood 59(1):114–123PubMed
2.
Tamary H, Kaplinsky C, Shvartzmayer S, Umiel T, Pecht M, Levin S et al (1993) Transient erythroblastopenia of childhood. Evidence for cell-mediated suppression of erythropoiesis. Am J Pediatr Hematol Oncol 15(4):386–391PubMed
3.
Sewell WA, Jolles S (2002) Immunomodulatory action of intravenous immunoglobulin. Immunology 107(4):387–393PubMedCrossRef
4.
Amran D, Renz H, Lack G, Bradley K, Gelfand EW (1994) Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 73(2):180–186PubMedCrossRef
5.
Ronda N, Haury M, Nobrega A, Coutinho A, Kazatchkine MD (1994) Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 70(2):124–128PubMedCrossRef
Metadata
Title
Immune aregenerative anemia without erythroblastopenia: a previously undescribed condition
Authors
V. Brousse
C. Brouzes
F. Sicre de Fontbrune
N. Casadevall
B. Varet
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1696-2

Other articles of this Issue 9/2013

Annals of Hematology 9/2013 Go to the issue

Letter to the Editor

Michelangelo's John the Baptist and thalassemia

Original Article

Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or chemotherapy

Original Article

Computerized image analysis of iron-stained macrophages

Letter to the Editor

Retroperitoneal follicular lymphoma presenting with gastric varices and splenic artery pseudoaneurysm

Original Article

A promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate aplastic anemia

Letter to the Editor

Sustained complete remission in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm following autologous peripheral blood stem cell transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits